Atsuyuki Igarashi

6.6k citations

89 papers · 4.7k indexed · 2 hit papers · h-index 31

Dermatology top 0.1%
- Dermatology and Skin Diseases 40
- Dermatologic Treatments and Research 10
Immunology and Allergy top 1%
- Allergic Rhinitis and Sensitization 14
Immunology top 2%
- Psoriasis: Treatment and Pathogenesis 29
Pathology and Forensic Medicine top 1%
- Systemic Sclerosis and Related Diseases 14
- Autoimmune Bullous Skin Diseases 13
Rheumatology top 1%
- Urticaria and Related Conditions 8
Physiology
- Asthma and respiratory diseases 13

Co-authors: Gary R. Grotendorst Douglass M. Bradham Robert Potter Kazuhiko Takehara Hitoshi Okochi Hidemi Nakagawa Kanako Kikuchi Shinichi Sato
Cited by: Dermatology Immunology and Allergy Immunology
Partner nations: Japan United States Germany

In The Last Decade

Atsuyuki Igarashi

87 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

1993 Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair.
1991 Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10.

Peers

Countries citing papers authored by Atsuyuki Igarashi

Since Specialization

Citations

This map shows the geographic impact of Atsuyuki Igarashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atsuyuki Igarashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atsuyuki Igarashi more than expected).

Fields of papers citing papers by Atsuyuki Igarashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atsuyuki Igarashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atsuyuki Igarashi. The network helps show where Atsuyuki Igarashi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Atsuyuki Igarashi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Atsuyuki Igarashi Line = papers co-authored together Atsuyuki Igarashi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Current Status of Prurigo Nodularis in Japan: A Retrospective Study Using a Health Insurance Claims Database Atsuyuki Igarashi,Takuo Yoshida,Yoshinori Sunaga,Hisakatsu Nawata,Kazuhiko Arima	2025	1
2	Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study Mamitaro Ohtsuki,Yukari Okubo,Hidehisa Saeki,Atsuyuki Igarashi,Shinichi Imafuku,Masatoshi Abe,Siddharth Chaudhari,Masafumi Yaguchi,Ayumi Emoto,Akimichi Morita	2024	3
3	Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials Atsuyuki Igarashi,Gaku Tsuji,Shuichi Fukasawa,Ryusei Murata,Satoshi Yamane	2024	13
4	English version of Japanese guidance for biologics in treating atopic dermatitis Hidehisa Saeki,Masashi Akiyama,Masatoshi Abe,Atsuyuki Igarashi,Shinichi Imafuku,Yukihiro Ohya,Norito Katoh,Hideto Kameda,Kenji Kabashima,Yuichiro Tsunemi,Michihiro Hide,Mamitaro Ohtsuki	2023	6
5	Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study Akihiko Asahina,Yukari Okubo,Akimichi Morita,Yayoi Tada,Atsuyuki Igarashi,Richard G. Langley,Delphine Deherder,Mizuho Matano,Veerle Vanvoorden,Maggie Wang,Mamitaro Ohtsuki,Hidemi Nakagawa	2023	9
6	English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis Hidehisa Saeki,Tomotaka Mabuchi,Akihiko Asahina,Masatoshi Abe,Atsuyuki Igarashi,Shinichi Imafuku,Yukari Okubo,Mayumi Komine,Kenzo Takahashi,Hideshi Torii,Akimichi Morita,Hiroshi Yotsuyanagi,Akira Watanabe,Mamitaro Ohtsuki	2023	6
7	Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis Mohamed Kamal,John D. Davis,Pavel Kovalenko,Kamal Srinivasan,Eric L. Simpson,Takeshi Nakahara,Makoto Sugaya,Atsuyuki Igarashi,Marius Ardeleanu,Christine Xu,Kazuhiko Arima	2022	4
8	Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1) Shinichi Imafuku,Hidemi Nakagawa,Atsuyuki Igarashi,Akimichi Morita,Yukari Okubo,Shigetoshi Sano,Yayoi Tada,Osamu Nemoto,Stephen J. Rozzo,Masaki Kawamura,Mamitaro Ohtsuki	2021	6
9	Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1) Atsuyuki Igarashi,Hidemi Nakagawa,Akimichi Morita,Yukari Okubo,Shigetoshi Sano,Shinichi Imafuku,Yayoi Tada,Masaru Honma,Alan M. Mendelsohn,Masaki Kawamura,Mamitaro Ohtsuki	2021	5
10	Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study Kristian Reich,Phoebe Rich,Catherine Maari,Robert Bissonnette,C. Leonardi,Alan Menter,Atsuyuki Igarashi,Paul Klekotka,Dipak Patel,J. Li,Jay Tuttle,MA Morgan-Cox,Emily Edson‐Heredia,S Friedrich,Kim Papp,(unknown)	2019	57
11	Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial Mamitaro Ohtsuki,Hideki Fujita,Masao Watanabe,Keiko Suzaki,Mary Flack,Xin Huang,Susumu Kitamura,Joaquin Valdes,Atsuyuki Igarashi	2019	79
12	Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks Kristian Reich,Richard B. Warren,Lars Iversen,L. Puig,Ignasi Pau‐Charles,Atsuyuki Igarashi,Mamitaro Ohtsuki,M. Falqués,Magda Harmut,Stephen J. Rozzo,Mark Lebwohl,Wendy Cantrell,Andrew Blauvelt,Diamant Thaçi	2019	107
13	A comparative phase III study of ozenoxacin lotion in patients with acne vulgaris Makoto Kawashima,Atsuyuki Igarashi,Nobukazu Hayashi,Yuichiro Tsunemi,Fujikawa Akira,Kato Rumiko,Watanabe Shin'ichi	2015	6
14	Japanese guidance for use of biologics for psoriasis (the 2013 version) Mamitaro Ohtsuki,Tadashi Terui,Akira Ozawa,Akimichi Morita,Shigetoshi Sano,Hidetoshi Takahashi,Mayumi Komine,Takafumi Etoh,Atsuyuki Igarashi,Hideshi Torii,Akihiko Asahina,Osamu Nemoto,Hidemi Nakagawa	2013	52
15	Impact of ustekinumab on health‐related quality of life in Japanese patients with moderate‐to‐severe plaque psoriasis: Results from a randomized, double‐blind, placebo‐controlled phase 2 / 3 trial Hidemi Nakagawa,Brad Schenkel,Mai Kato,Takeshi Kato,Atsuyuki Igarashi,(unknown)	2012	28
16	A Consensus Conference Report on Psoriasis Therapy with Cyclosporine MEPC Hidemi Nakagawa,Setsuya Aiba,Akihiko Asahina,Hajime Iizuka,Atsuyuki Igarashi,Yoshinori Umezawa,Takafumi Etoh,Mamitaro Ohtsuki,Akira Ozawa,Masahiro Takigawa,Juichiro NAKAYAMA,Hitoshi Mizutani,Osamu Nemoto,Masutaka Furue,Fukumi Furukawa,Akimichi Morita,Hitoshi Yaguchi,Kunio Morozumi	2004	7
17	DETECTION OF ANTIRIBOSOMAL P PROTEIN ANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS Manabu Fujimoto,Shinichi Sato,Kazuhiko Takehara,Yusuke Nojima,Y. Soma,Kanako Kikuchi,Hironobu Ihn,Atsuyuki Igarashi,K. Tamaki	1995	14
18	Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma Hironobu Ihn,Manabu Fujimoto,Shinichi Sato,Kanako Kikuchi,Atsuyuki Igarashi,Yoshinao Soma,Kazuhiko Takehara	1994	28
19	Dipyridamole specifically decreases platelet-derived growth factor release from platelets Kazuhiko Takehara,Atsuyuki Igarashi,Y. Ishibashi	1990	11
20	Mitogenic activities for skin fibroblasts in the sera from untreated scleroderma patients at the early stage Atsuyuki Igarashi,Kazuhiko Takehara,Y. Soma,K. Kikuchi,Y. Ishibashi	1989	3

About Atsuyuki Igarashi

Atsuyuki Igarashi is a scholar working on Dermatology, Immunology and Allergy and Immunology, having authored 89 papers that have together received 4.7k indexed citations. Recurring topics across this work include Dermatology and Skin Diseases (40 papers), Psoriasis: Treatment and Pathogenesis (29 papers), Allergic Rhinitis and Sensitization (14 papers), Systemic Sclerosis and Related Diseases (14 papers), Autoimmune Bullous Skin Diseases (13 papers), Asthma and respiratory diseases (13 papers), Dermatologic Treatments and Research (10 papers) and Urticaria and Related Conditions (8 papers). The work is most often cited by research in Dermatology (1.6k citations), Immunology and Allergy (554 citations) and Immunology (1.4k citations). Atsuyuki Igarashi has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Gary R. Grotendorst, Douglass M. Bradham, Robert Potter, Kazuhiko Takehara, Hitoshi Okochi, Hidemi Nakagawa, Kanako Kikuchi, Shinichi Sato, Hironobu Ihn and Kiyoko Nashiro.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact